Dor BioPharma wins FDA fast track status for enteritis drug
For instance, should events warrant, Dor will be eligible to submit a new drug application (NDA) for DOR201 on a rolling basis, permitting the FDA to review sections
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.